Diseases /

Myeloproliferative Neoplasm, Unclassifiable

Back to Diseases List
Associated Genetic Biomarkers

Overview

NCI Definition: This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms. [1]

Myeloproliferative neoplasm, unclassifiables most frequently harbor alterations in JAK2, ASXL1, TET2, U2AF1, and SRSF2 [2].

Most Commonly Altered Genes in Myeloproliferative Neoplasm, Unclassifiable

JAK2 V617F, JAK2 Mutation, JAK2 Exon 14 Mutation, ASXL1fs, and TET2 Mutation are the most common alterations in myeloproliferative neoplasm, unclassifiable [2].

Top Alterations in Myeloproliferative Neoplasm, Unclassifiable

Clinical Trials

View Clinical Trials for Myeloproliferative Neoplasm, Unclassifiable

Significant Genes in Myeloproliferative Neoplasm, Unclassifiable

IDH1 +

IDH2 +

Disease Details

Synonyms
CMPD, U, MPN, U, Chronic Myeloproliferative Disorder, Unclassifiable, MPN-U, Unclassifiable Chronic Myeloproliferative Disease, Unclassifiable Chronic Myeloproliferative Disorder, CMPD-U, Chronic Myeloproliferative Disease, Unclassifiable
Parent(s)
Myeloproliferative Neoplasm
OncoTree Name
Myeloproliferative Neoplasms, Unclassifiable
OncoTree Code
MPNU

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.